180 Life Sciences Corp. Files S-1/A Amendment
Ticker: FRMM · Form: S-1/A · Filed: Jan 31, 2025 · CIK: 1690080
| Field | Detail |
|---|---|
| Company | 180 Life Sciences CORP. (FRMM) |
| Form Type | S-1/A |
| Filed Date | Jan 31, 2025 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $1.41, $10,000,000, $0, $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-statement, amendment
TL;DR
180 Life Sciences Corp. (formerly KBL Merger Corp. IV) filed an S-1/A on Jan 31, 2025. Pharma prep co. in Palo Alto, CA.
AI Summary
180 Life Sciences Corp. filed an S-1/A amendment on January 31, 2025, for its registration statement. The company, formerly known as KBL Merger Corp. IV until November 15, 2016, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 3000 El Camino Real, Palo Alto, CA.
Why It Matters
This filing indicates ongoing regulatory activity for 180 Life Sciences Corp., which could impact its stock and future business operations.
Risk Assessment
Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate changes, which carry inherent market risks.
Key Numbers
- 333-280912 — SEC File Number (Identifies the specific registration statement)
- 25578766 — Film Number (Internal SEC processing number)
- 0001690080 — Central Index Key (Unique identifier for the filer)
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- KBL Merger Corp. IV (company) — Former company name
- January 31, 2025 (date) — Filing date
- November 15, 2016 (date) — Date of name change
- 3000 El Camino Real, Bldg. 4, Suite 200 Palo Alto, CA 94306 (address) — Principal executive offices
- Blair Jordan (person) — Interim Chief Executive Officer
FAQ
What is the purpose of this S-1/A filing?
This is an Amendment No. 3 to Form S-1, indicating updates or revisions to the original registration statement filed by 180 Life Sciences Corp.
When was 180 Life Sciences Corp. previously known by another name?
The company was formerly known as KBL Merger Corp. IV, with a date of name change on November 15, 2016.
What industry does 180 Life Sciences Corp. operate in?
The company is classified under Pharmaceutical Preparations [2834].
Where are the principal executive offices of 180 Life Sciences Corp. located?
The principal executive offices are located at 3000 El Camino Real, Bldg. 4, Suite 200, Palo Alto, CA 94306.
Who is the interim CEO of 180 Life Sciences Corp.?
Mr. Blair Jordan is the Interim Chief Executive Officer.
Filing Stats: 4,561 words · 18 min read · ~15 pages · Grade level 17.1 · Accepted 2025-01-31 16:30:45
Key Financial Figures
- $1.41 — stock, at an assumed offering price of $1.41 per unit, which is equal to the closing
- $10,000,000 — y 29, 2025, for gross proceeds of up to $10,000,000. The actual public offering price will
- $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
- $0.0001 — ncluded in the pre-funded units will be $0.0001 per share. The pre-funded warrants will
Filing Documents
- ea0228452-s1a3_180life.htm (S-1/A) — 1052KB
- ea022845201ex23-1_180life.htm (EX-23.1) — 3KB
- image_001.jpg (GRAPHIC) — 13KB
- image_002.jpg (GRAPHIC) — 21KB
- 0001213900-25-008868.txt ( ) — 1103KB
Risk Factors
Risk Factors 19 Incorporation by Reference 48
Use of Proceeds
Use of Proceeds 49 Capitalization 51
Dilution
Dilution 53 Dividend Policy 55 Beneficial Ownership of Securities 56 Executive and Director Compensation 58 Plan of Distribution 72
Description of Capital Stock
Description of Capital Stock 78
Description of Securities We Are Offering
Description of Securities We Are Offering 82 Legal Matters 86 Experts 86 Where You Can Find More Information 86 i Our logo and some of our trademarks and tradenames are used in this prospectus. This prospectus also includes trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames and service marks referred to in this prospectus may appear without the ®, ™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, reports by market research firms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or survey data that is presented in this prospectus. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe these industry publications and third-party research, surveys and studies are reliable, provided that we have not commissioned any such information. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as the